Compare WOR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | TGTX |
|---|---|---|
| Founded | 1955 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 5.5B |
| IPO Year | N/A | 1995 |
| Metric | WOR | TGTX |
|---|---|---|
| Price | $58.06 | $31.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $61.00 | $54.75 |
| AVG Volume (30 Days) | 141.9K | ★ 1.6M |
| Earning Date | 12-16-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 179.34 | N/A |
| EPS | 2.14 | ★ 2.78 |
| Revenue | ★ $1,200,161,000.00 | $531,898,000.00 |
| Revenue This Year | $14.93 | $87.88 |
| Revenue Next Year | $4.45 | $48.75 |
| P/E Ratio | $27.27 | ★ $11.29 |
| Revenue Growth | 0.76 | ★ 100.88 |
| 52 Week Low | $37.88 | $25.28 |
| 52 Week High | $70.91 | $46.48 |
| Indicator | WOR | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.98 | 47.58 |
| Support Level | $54.59 | $29.50 |
| Resistance Level | $55.79 | $32.26 |
| Average True Range (ATR) | 1.04 | 1.06 |
| MACD | 0.49 | 0.05 |
| Stochastic Oscillator | 98.12 | 44.11 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.